Sign Out
Consult the physician if any of the following signs occur while taking this medication, these are feeling of discomfort, headaches, nausea, or other gastrointestinal upsets, breast tenderness, spotting or break bleeding.
B-LADY may increase the risk of thromboembolism; discontinue use if an arterial or venous thrombotic event occurs.
Progesterone and/or estrogen should not be taken while on B-LADY.
The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women > 35 years of age) and the number of cigarettes smoked (≥ 15 cigarettes per day); women who use B-LADY should be strongly advised not to smoke.
May have adverse effects on glucose tolerance; use caution in woman with diabetes. If patient has diabetes, hypertension, and obesity or if this triad of conditions develops, B-LADY should be discontinued.
Malignant liver tumors leading to isolated cases of life-threatening intraabdominal hemorrhage have been observed. If severe upper-abdominal complaints, liver enlargement or signs of intra-abdominal hemorrhage occur a liver tumors should be included in the differential diagnostic considerations.
Use with caution in patients with hepatic or renal impairment, cardiac disease, depression, asthma, epilepsy, or history of migraine. Estrogen may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema. Discontinuation of B-LADY may be necessary.
B-LADY may change the results of some laboratory test (e.g. coagulation factors, lipids, glucose tolerance, binding proteins).
